文献速递乳房整形与再造显微修复重建

DIEP皮瓣乳房再造中加速康复路径联合脂质体布比卡因的疗效

Defining Enhanced Recovery Pathway with or without Liposomal Bupivacaine in DIEP Flap Breast Reconstruction.
PubMed 文献 · Plast Reconstr Surg · 2021-01-01

该回顾性研究纳入216例DIEP皮瓣乳房再造患者,比较ERAS前、ERAS中及ERAS联合脂质体布比卡因三组的术后阿片类药物消耗和住院时间。结果显示ERAS降低阿片消耗和住院时间,加用脂质体布比卡因进一步强化效果。

要点

  • ERAS方案可降低DIEP皮瓣乳房再造术后阿片消耗和住院时间
  • 加用脂质体布比卡因腹横肌平面阻滞进一步减少阿片消耗和住院时间
  • 证据等级为治疗性III级

核心结论

  • ERAS方案降低DIEP皮瓣乳房再造术后阿片消耗和住院时间,加用脂质体布比卡因进一步强化效果。

研究设计与样本

  • 共分析216例患者:ERAS前组67例,ERAS组69例,ERAS联合脂质体布比卡因组80例。

主要发现

  • 术后阿片消耗从ERAS前组的275.7口服吗啡当量降至ERAS组的146.7(p<0.0001),加用脂质体布比卡因后进一步降至115.3(p=0.016)。
  • 住院时间从ERAS前组的3.6天降至ERAS组的3.2天(p=0.0029),ERAS联合脂质体布比卡因组降至2.6天(p<0.0001)。

临床怎么用

  • 在DIEP皮瓣乳房再造中实施ERAS方案,并可考虑加用脂质体布比卡因腹横肌平面阻滞以进一步减少阿片消耗和缩短住院时间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Enhanced recovery after surgery (ERAS) includes multiple interventions that have yielded positive outcomes in a number of surgical fields. The authors evaluated whether an ERAS protocol and the subsequent addition of liposomal bupivacaine affect patient outcomes specifically in deep inferior epigastric perforator (DIEP) flap breast reconstruction. METHODS: All patients treated with DIEP flaps from January of 2016 to December of 2019 were reviewed retrospectively. The ERAS protocol was implemented midway through 2017; halfway through 2018, intraoperative transversus abdominis plane blocks with liposomal bupivacaine were added to the protocol. Such interventions allowed for comparison of three patient groups: before ERAS, during ERAS, and after ERAS plus liposomal bupivacaine. Primary outcomes observed were postoperative opioid consumption and length of stay. The p values were obtained using the Wilcoxon test for pairwise comparisons. RESULTS: After adjusting for ERAS group compliance, 216 patients were analyzed. The pre-ERAS group was composed of 67 patients, the ERAS group was composed of 69 patients, and the ERAS plus liposomal bupivacaine group was composed of 80 patients. Postoperative opioid consumption was reduced when comparing the pre-ERAS and ERAS groups (from 275.7 oral morphine equivalents to 146.7 oral morphine equivalents; p < 0.0001), and also reduced with the addition of liposomal bupivacaine (115.3 oral morphine equivalents; p = 0.016). Furthermore, hospital length of stay was decreased from 3.6 days in the pre-ERAS group to 3.2 days (p = 0.0029) in the ERAS group, and to 2.6 days (p < 0.0001) in the ERAS group plus liposomal bupivacaine groups. CONCLUSIONS: Enhanced recovery after surgery protocols decrease postoperative opioid consumption and hospital length of stay in DIEP flap breast reconstruction. The addition of liposomal bupivacaine further strengthens the impact of the protocol. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. Haddock NT, Garza R, Boyle CE, et al. Defining Enhanced Recovery Pathway with or without Liposomal Bupivacaine in DIEP Flap Breast Reconstruction. Plast Reconstr Surg. 2021. PMID: 34705768. doi:10.1097/PRS.0000000000008409

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。